After a Reset Year, Is Moderna Stock Poised for a Comeback?
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
Why I Don’t Believe Larry Ellison’s Moderna Stock Hype
CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...
Moderna: Is Stock a Buy? Breaking Down the Latest Guidance
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Yeni Şafak2d
Experts at Davos warn of grave threat to global health from climate change
Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...
Sick of the stomach bug? Moderna is making a norovirus vaccine
Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.
A norovirus vaccine could be on the horizon as cases rise
Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.
Moderna, Inc. (NASDAQ:MRNA) institutional owners may be pleased with recent gains after 65% loss over the past year
To get a sense of who is truly in control of Moderna, Inc. ( NASDAQ:MRNA ), it is important to understand the ownership structure of the business. With 69% stake, institutions possess the maximum ...
Jim Cramer Says Moderna, Inc. (MRNA) Has Been ‘One Of The Biggest Disappointments Of The Year’
We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...
Insider Monkey6d
These 10 Firms Were Last Week’s Worst Performers
Moderna (NASDAQ:MRNA) CEO Stéphane Bancel said that the vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million in 2026. It expects to end 2025 with ...